Vaccine plus Keytruda for lung cancer after surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that is stage II, IIIA, or IIIB (N2) and has not been treated yet.
- You should have already received chemotherapy plus pembrolizumab before surgery, and after surgery, the cancer was not completely gone.
- Your tumor must not have certain gene changes (like EGFR or ALK) that would make other targeted treatments more appropriate.
- You must not have had prior immunotherapy (like Keytruda) or a cancer vaccine for any condition.
- You need to be in generally good health (able to perform daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two immunotherapy drugs (iparomlimab and tuvonralimab) with 2 or 4 cycles of chemotherapy before surgery for patients with stage II to IIIB non-small cell lung cancer that can be removed. It aims to see if this approach helps shrink tumors and improve outcomes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This study tests a new personalized cancer vaccine (V940) plus Keytruda versus a placebo plus Keytruda for people with non-small cell lung cancer that was removed by surgery. The goal is to see if the vaccine helps prevent the cancer from coming back.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests adding the immunotherapy drug Adebrelimab to chemotherapy before surgery for people with a type of lung cancer that has certain gene changes. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial is testing a new combination of drugs (including pembrolizumab) as a treatment before surgery for people with a certain type of lung cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.